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ABSTRACT 
Mushrooms represent an unlimited source of compounds with antitumor and 
immunostimulating properties and mushroom intake as been shown to reduce the risk of 
breast cancer. A large number of LMW (low molecular weight) compounds present in 
mushrooms have been identified including: phenolic acids, flavonoids, tocopherols, 
carotenoids, sugars and fatty acids. In order to evaluate which wild mushroom LMW 
compounds may be involved in anti-breast cancer activity we selected a representative 
dataset of 43 LMW compounds and performed molecular docking against 3 known 
protein targets involved in breast cancer (Aromatase, Estrone Sulfatase and 17β-HSD-1) 
using AutoDock4 as docking software. The estimated inhibition constants for all LMW 
compounds were determined and the potential structure-activity relationships for the 
compounds with the best estimated inhibition constants are discussed for each 
compound family. 4-O-caffeoylquinic, naringin and lycopene stand out as the top 
ranked potential inhibitors for Aromatase, Estrone Sulfatase and 17β-HSD1, 
respectively, and the 3-D docked conformation for these compounds are discussed in 
detail. This information provides several interesting starting points for further 
development of Aromatase, Estrone Sulfatase and 17β-HSD1 inhibitors. 
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1. Introduction  
Mushrooms comprise a vast and yet largely untapped source of powerful new 
pharmaceutical products. In particular, and most importantly for modern medicine, they 
represent an unlimited source of compounds with antitumor and immunostimulating 
properties [1-3]. Mushrooms contain compounds known as long-chain, large-molecular 
weight polysaccharides which, when present in specific configurations or linkages (beta, 
1-3 glucan and beta, 1-6 glucan), have strong effects on the immune system of humans 
[4-6]. Several phytochemicals have been isolated from medicinal mushrooms and three 
of these, which are carcinostatic polysaccharide drugs, have been developed from 
mushrooms in Japan. These are “Krestin” (PSK), from the cultured mycelium of 
Kawaratake (Trametes versicolor), “Lentinan” from the fruiting bodies of Shiitake 
(Lentinus edodes) and “Schizophyllan” (Sonifilan) from the culture fluid of Suehirotake 
(Schizophyllum commune) [7,8]. More importantly extracts from wild mushrooms 
species have been shown to reduce the risk of breast cancer in Chinese women [9] and 
in breast cancer cell lines [10]. Mushrooms are also rich sources of low molecular 
weight (LMW) antioxidant compounds mainly phenolic compounds (phenolic acids and 
flavonoids), followed by tocopherols, ascorbic acid and carotenoids as described by our 
research group [11]. In fact, in the last years tens of different mushroom species from 
Northeast of Portugal, one of the European regions with higher wild edible mushrooms 
diversity, were evaluated by us, for their composition on those LMW compounds [12-
18]. Since the non-controlled production of free radicals has been related to more than 
one hundred diseases including several kinds of cancer, it was our goal to evaluate the 
potential properties of the LMW compounds found in mushrooms against some proteins 
identified as targets in breast cancer.  
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Most breast cancers (about 95%), whether in pre- or post-menopausal women, 
are initially hormone-dependent and it is well accepted that estradiol plays an important 
role in their development and progression. Estradiol in complex with their receptor can 
mediate the activation of proto-oncogenes or oncogenes (e.g. c-fos, c-myc), nuclear 
proteins, as well as other target genes. Consequently, processes that modulate the 
intracellular concentrations of active estrogens can have the ability to affect the etiology 
of this disease. It is known that that mammary cancer tissue contains all the enzymes 
responsible for the local biosynthesis of estradiol from circulating precursors [19]. Two 
principal pathways are implicated in the last steps of estradiol formation in breast 
cancer: the „Aromatase pathway‟, with Aromatase enzyme (EC: 1.14.14.1) that converts 
androgens into estrogens and the „Sulfatase pathway‟ which converts estrone sulfate 
into estrone by the action of Estrone Sulfatase enzyme (EC: 3.1.6.2). The final step of 
steroidogenesis is the conversion of the weak estrone to the potent biologically active 
estradiol by the action of a reductive 17-hydroxysteroid dehydrogenase type 1 enzyme 
(17β-HSD-1; EC: 1.1.1.62) [19]. 
Intermolecular interactions between proteins and small ligands play essential 
roles in several life processes and understanding these interactions is critical for 
pharmaceutical and functional food industries [20]. Molecular docking is an in silico 
tool that predicts how a ligand (substrate or drug candidate) interacts with a receptor 
usually by predicting the ligand free energy of binding and the three-dimensional 
structure of the ligand-receptor complex. The use of molecular docking to search large 
databases of compounds for possible ligands of a protein receptor is usually termed 
virtual screening and has been successfully applied in several therapeutic programs at 
the lead discovery stage [21]. In this work we use AutoDock4 [22], acknowledged to be 
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one of the most reliable and broadly used molecular docking tool [23] with several 
examples of accurate docking predictions already published [24-26]. 
In the present study we performed molecular docking using 3-D structures of 
Aromatase, Estrone Sulfatase and 17β-HSD-1 as targets and phenolic acids, flavonoids, 
tocopherols, carotenoids, sugars and fatty acids as ligands. The main goal was to 
identify LMW wild mushrooms compounds with potential activity against human breast 
cancer by identifying the potential protein targets. Also the molecular basis of the 
interaction between the best LMW compounds identified and the selected protein 
targets is discussed. 
 
2. Methodology 
2.1. LMW compound dataset 
The LMW compound dataset used was composed of 43 compounds 
representative of the chemical composition of wild mushrooms [11-18]. The 2-D 
structure of the dataset was constructed using the MDL Isis/Draw 2.5 software 
(http://www.symyx.com). The software VegaZZ 2.3.1 [27] was then used to: convert all 
compounds to 3-D, perform energy minimization and record files in pdb format. Next, 
AutoDockTools1.5.2 (ADT) [28] was used to: merge nonpolar hydrogens, add 
Gasteiger charges, and set up rotatable bonds through AutoTors [29]. Finally all 
compounds were recorded in pdbqt file format, a format needed for docking with 
AutoDock4. 
 
2.2. Protein structures preparation 
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The X-ray 3-D structures of the protein targets used were extracted from the 
Protein Data Bank (PDB) (http://www.rcsb.org) including: Aromatase (PDB: 3EQM), 
Estrone Sulfatase (PDB: 1P49) and 17β-HSD1 (PDB: 1FDT). 
For 3EQM and 1FDT the co-crystallized ligand (Androstenedione and Estrone 
respectively) was extracted from the PDB file (Table 1). This procedure was not done 
with 1P49 structure because this structure was determined without a co-crystallized 
ligand. ADT was then used to assign polar hydrogens and Gasteiger charges to the 
protein structures and the structures where also recorded in pdbqt format [22]. 
For each protein structure, AutoGrid4 [22] was used to create affinity grid maps 
for all the atoms types present on the protein and compounds. We used ADT to choose 
the correct parameters before using AutoGrid4. All affinity grid maps were centred on 
the active site and coordinates were selected in order to encompass all the active site for 
each protein. 3EQM affinity grids enclosed an area of 100 Å by 100 Å by 100 Å with 
0.375 Å spacing, centred on the coordinates x=86.312 y=51.204 z=48.26, 1P49 affinity 
grids maps enclosed an area of 80 Å by 80 Å by 80 Å with 0.375 Å spacing, centred on 
the coordinates x=71.9 y=-5.072 z=30.368 and 1FDT affinity grids enclosed an area of 
80 Å by 110 Å by 110 Å with 0.375 Å spacing, centred on the coordinates x=39.685 
y=1.159 z=37.333.  
 
2.3. Molecular docking using AutoDock4 
AutoDock4 (version 4.0.1) with the Lamarckian genetic algorithm was used to 
simulate compound-protein molecular docking for the 3 selected protein structures [22]. 
Docking parameters selected for AutoDock4 runs were as follows: 50 docking runs, 
population size of 200, random starting position and conformation, translation step 
ranges of 2.0 Å, mutation rate of 0.02, crossover rate of 0.8, local search rate of 0.06, 
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and 2.5 million energy evaluations. Docked conformations were clustered using a 
tolerance of 2.0 Å RMSD (Root Mean Square Deviation). The entire virtual experiment 
was performed on a cluster of 8 Intel Dual-Core 2.8 GHz computers using a custom 
designed software called MOLA [30]. Estimated inhibition constant (Ki) values for all 
compounds were calculated by AutoDock4 as follows: Ki = 
exp((ΔG*1000)/(Rcal*TK)) where ΔG is the binding energy, Rcal is 1.98719 and TK is 
298.15. The Michaelis-Menten constant (Km) values for natural ligands presented on 
table 1 were calculated by AutoDock4 using the same equation presented above and the 
pKm values were calculated using the following equation: pKm = log (1/Km). The 3-D 
compound-protein docking poses were analysed manually using ADT and the images 
presented on figures 1 and 3 were prepared using the software PyMOL 0.99r6 
(http://pymol.sourceforge.net/). 
 
3. Results and Discussion 
3.1. Molecular Docking validation 
In order to validate the molecular docking approach for the protein structures 
studied, the respective ligands (natural substrates) were docked to the active site of the 
proteins (from which the natural ligands were previously removed). Then the estimated 
binding energy (ΔG) and Km values obtained were compared with experimental ΔG 
and Km values (Table 1). Also the estimated 3-D binding pose was compared with the 
experimental (by X-ray crystallography) co-crystallized binding pose (Fig. 1).  
 The authors of AutoDock4 used a large number of protein-ligand complexes to 
calibrate AutoDock4's algorithm and the binding energy model they used exhibited a 
residual standard error of 2.177 kcal/mol [22]. For Aromatase, Estrone Sulfatase and 
17β-HSD1, when comparing estimated and experimental ΔG values, we observed 
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differences of 0.95, 1.60 and 0.42 Kcal/mol respectively (Table 1). These variations fall 
well within the residual standard error of 2.177 kcal/mol observed for AutoDock4. This 
is a strong indication that AutoDock4 is performing well with the selected protein 
structures thus validating them for docking with other LMW compounds. 
When calculating Km (or Ki) values from ΔG values, the 2,177 kcal/mol 
standard error translates into an expected 1.6 orders of magnitude (pKm difference) 
accuracy for AutoDock4. In our study, the estimated Km calculated by AutoDock4 was 
5 times lower than experimental Km for Aromatase (difference of 0.6 orders of 
magnitude), 20 times lower for Estrone Sulfatase (difference of 1.2 orders of 
magnitude) and 2 times higher for 17β-HSD1 (difference of 0.3 orders of magnitude) 
(Table 1). These values are well within the 1.6 orders of magnitude difference 
considered acceptable for AutoDock4. 
Also the binding mode of the docked ligands for Aromatase and 17β-HSD1 
corresponded well with the binding mode of the co-crystallized ligands, with RMSD 
values of 0.08 Ǻ and 0.66 Ǻ, respectively (Fig. 1 and Table 1). These values shows that 
the difference between the X-ray conformation and the predicted docked conformations 
of the compounds was very small thus validating further the protein structures for 
molecular docking with the LMW compound dataset. Particularly, for both 
Androstenedione (Fig. 1A) and Estrone (Fig. 1B), we can see that AutoDock4 
accurately predicted the position of the atoms that form hydrogen bonds with residues 
of the catalytic sites. 
This comparison is not possible for Estrone Sulfatase as there is no 
experimentally determined structure with a co-crystallized ligand, only the non-bounded 
protein structure. This probably explains the higher different between estimated and 
experimental Km for Estrone Sulfatase (1.60 Kcal/mol) although still well within the 
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expected standard error and thus the structure was validated for docking using 
AutoDock4. 
 
3.2. Molecular Docking of the LMW Mushrooms compounds  
We then performed molecular docking using AutoDock4 with the selected wild 
mushroom LMW compound dataset against the 3 target structures. The dataset used is 
not exhaustive but is a good representation of the different LMW families of 
compounds that can be found in wild mushrooms. The results will be discussed for each 
family of compounds: phenolic compounds (benzoic acid and cinnamic acid derivatives, 
and flavonoids), vitamins (tocopherols and ascorbic acid), carotenoids, sugars and fatty 
acids.  
The results obtained using phenolic acids (Table 2) revealed that benzoic acid 
derivatives appear to have no significant inhibitory activity against the 3 enzymes 
studied with all values well above 1 μM. Cinnamic acid derivatives also had no 
significant inhibitory activity except for 4-O-caffeylquinic and 5-O-caffeylquinic which 
presented moderate inhibition activity for the enzymes with values in the hundreds of 
nM (Fig. 2 and Table 2). The presence of quinic acid seems to be an essential condition 
for phenolic acid inhibition. Also the fact that 4-O-caffeylquinic and 5-O-caffeylquinic 
present activity against all the 3 enzymes probably results from the fact that they have 
similar structures to the natural ligands. This simultaneous inhibition activity may result 
in a synergistic inhibition of overproduction of estrone in breast cancer by inhibiting 
both “Aromatase” and “Sulfatase” pathway as well as inhibiting estradiol to estrogen 
conversion by 17β-HSD1. 
The results obtained using flavonoids (Table 3) showed that quercetin was the 
best compound to inhibit Aromatase, with naringin being the best for Estrone Sulfatase 
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and 17β-HSD1. Interestingly, the substitution of the hydroxyl group for the disaccharide 
rutinose increases estimated Ki values for Aromatase and decreases the corresponding 
values for the other two enzymes (see in Table 3 and Fig. 2 rutin relative to quercetin 
and naringin relative to naringenin). The presence of rutinose in those compounds might 
increase the stereochemical hindrance of the molecules decreasing their binding 
capacity to Aromatase, which contains a Heme group. In general, we observed that a 
good number of the flavonoids from different groups present inhibition activity. This is 
probably because, from all the LMW compounds used, flavonoids have more similar 
structures to the natural ligands. 
The results obtained using vitamins and carotenoids are given in Table 4. 
Vitamin E (tocopherols) proved to have better binding capacity than vitamin C 
(ascorbic acid). The four isoforms of vitamin E (α, β, δ, and γ-tocopherol) revealed very 
good inhibition properties for 17β-HSD1 with estimated Ki in the nanomolar range. 
Furthermore, β-carotene and lycopene revealed excellent properties for inhibition of 
17β-HSD1 with lycopene estimated Ki in the subnanomolar range (0.2 nM), the best 
result of all compounds. Also, α, δ, and γ-tocopherol showed moderate inhibition 
activity against Estrone Sulfatase. 
In relation to the results obtained using sugars and fatty acids (Table 5) it was 
not observed any significant inhibition activity in any of the studied targets. Only 
maltose showed a very moderate activity against 17β-HSD1 but with a relatively high 
estimated Ki value (0.605 μM); interestingly maltose is the only reducing sugar which 
may be an important factor as 17β-HSD1 is a dehydrogenase enzyme. Nevertheless the 
studied sugars and fatty acids do not seem implicated in anti-breast cancer activity.  
 
3.3 Binding mode analysis of the top ranked LMW Mushrooms compounds 
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The docked binding mode of all the compounds with good estimated Ki values 
was manually inspected in order to verify that they effectively bind to the catalytic site 
in a structurally viable conformation.  
For Aromatase the top ranked compound was 4-O-caffeoylquinic and the docked 
structure occupies the space where the natural ligand Androstenedione binds (Fig. 3A). 
The aromatic rings from 4-O-caffeoylquinic occupies the space of the aromatic rings of 
Androstenedione and the quinic acid seems to be the key with the carboxylic acid 
stabilized by polar contacts with the Heme group of Aromatase. Also probably 4-O-
caffeoylquinic mimics Androstenedione forming hydrogen bonds with ARG-115 and 
the peptide bond between VAL-373 and MET-374 of Aromatase (Fig. 1A). This is 
possible because one oxygen of 4-O-caffeoylquinic is positioned on the same space 
occupied by the oxygen of one of Androstenedione's carbonyl group (Fig. 3A). It‟s 
important to note that the estimated Ki values (315 nM for 4-O-caffeoylquinic) obtained 
with Aromatase as the protein target was at least one order of magnitude higher than the 
experimental Km value obtained with Androstenedione (20 nM). This fact indicates that 
Aromatase is probably not the most important target for LMW compounds in wild 
mushrooms.  
For Estrone Sulfatase inhibition the top ranked compound was the flavanone 
naringin (Fig. 3B; Table 4). The disaccharide rutinose seems to play a pivotal role in 
naringin inhibition by promoting hydrogen bonds with the sulfate group present. The X-
ray structure used for docking had no co-crystallized ligand. The estimated Ki value 
obtained for naringin (206 nM) was well below the experimental Km of the natural 
ligand estrone sulfate (6850 nM). Also several compounds have estimated Ki values in 
the order of naringin. These data indicates that several LMW compounds could be 
working synergistically and that probably the “Sulfatase” pathway is the most likely 
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target for LMW wild mushrooms compounds against breast cancer. This is even more 
interesting in view of recent findings in human breast cancer that point towards 
“Sulfatase” pathway as the most likely path for estradiol production with “Aromatase” 
pathway playing a secondary role [19]. 
Finally 17β-HSD1 was the most susceptible protein target with the lowest 
estimated Ki values of all the dataset. Lycopene (Fig. 3C; Table 4) presented the best 
estimated Ki value (0.2 nM) about three orders of magnitude lower than the 
experimental Km value for the natural ligand estrone (124 nM). Analysing the docked 
structure (Fig. 3C) we can see that lycopene “fits” exactly on the binding pocket 
occupied by the co-enzyme NADPH and the natural ligand estrone. Because lycopene is 
predominantly a hydrophobic compound, its structure is stabilized by van der Walls 
interactions and no so much by the hydrogen bonds that stabilize the natural ligand 
estrone (Fig. 1A). It is important to note that, although the estimated Ki value was very 
low, its inhibition ability is probably balanced by the difficulty of lycopene to reach the 
binding site of 17β-HSD1 due to low solubility in water. 
 
4. Conclusions 
In conclusion, this study highlights several LMW compounds from wild 
mushrooms that may act against breast cancer by inhibiting different proteins involved 
in overproduction of estrone and estradiol. From the phenolic acids studied the cinnamic 
acid derivatives esterified with quinic acid (4 and 5-O-caffeylquinic acid) were the only 
compounds with significant inhibition against the 3 protein targets studied, specially 4-
O- caffeoylquinic acid that presented the best estimated Ki against Aromatase. Among 
flavonoids several compounds presented moderate to good inhibition ability with 
flavanones (naranigenin and naringin) and flavonols (quercetin and rutin) with the best 
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estimated Ki values. Naringin was the top ranked inhibitor against Estrone Sulfatase 
indicating that the presence of the disaccharide rutinose may be a key element for active 
compounds against breast cancer. Vitamins and carotenoids were target specific 
showing very good inhibition ability only against 17β-HSD1, with lycopene as the top 
ranked inhibitor. Sugar and fatty acids did not show any significant inhibition ability. 
This study suggests the LMW compounds to look for in wild mushrooms when 
searching for species with anti-breast cancer activity. Furthermore, the information 
provided shows several interesting starting points for further development of 
Aromatase, Estrone Sulfatase and 17β-HSD1 inhibitors. 
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Table 1 
Estimated and experimental values of Km (nM) and ΔG (Kcal/mol) for the natural 
ligand of Aromatase, Estrone Sulfatase and 17β-HSD1. 
Enzyme 
Aromatase 
(PDB: 3EQM) 
Estrone Sulfatase 
(PDB: 1P49) 
17β-HSD1 
(PDB: 1FDT) 
Ligand Androstenedione Estrone Sulfate Estrone 
Experimental ΔG (Kcal/mol) -10,51 -7,04 -9,44 
Estimated ΔG (Kcal/mol) -11,46 -8,7 -9,02 
ΔG difference -0,95 -1,66 0,42 
Experimental Km (nM)      20 
[31]      6850 [32]      124 [33] 
Estimated Km (nM) 4 416 238 
pKm diference* 0,6 1,3 0,3 
RMSD** 0,08 Ǻ - 0,66 Ǻ 
*pKm diference = (Estimated pKm – Experimental pKm). 
**RMSD: Root Mean Square Deviation. 
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Table 2 
Docking studies with phenolic acids found in wild mushrooms. 
 
 
R3
R4
R2 R1
X
    
CHR3
R4
R2
CH C
O
O
X
R1
 
   
* The carboxylic group is esterified with quinic acid. 
Benzoic acid 
derivatives 
Substitution Estimated Ki (µM) 
X R
1 
R
2 
R
3 
R
4 
Aromatase 
Estrone 
Sulfatase 
17β-HSD1 
p-Hydroxibenzoic COOH H H H OH 607.4 278.3 101.6 
Protocatechuic COOH H H OH OH 365.9 155.0 102.2 
Gallic COOH H OH OH OH 358.3 129.2 100.6 
Gentisic COOH OH H H OH 546.1 599.0 578.3 
Homogentisic CH2COOH OH H H OH 939.4 583.9 116.4 
Vanillic COOH H OCH3 OH H 227.0 98.08 89.70 
5-Sulphosalicylic COOH OH H H HSO3 219.7 381.8 365.5 
Syringic COOH H OCH3 OH OCH3 239.9 212.4 93.68 
Veratric COOH H OCH3 OCH3 H 309.4 98.04 98.60 
Vanillin CHO* H OCH3 OH H 213.5 299.4 >1000 
Cinnamic acid 
derivatives 
Substitutions Estimated Ki (µM) 
X R
1 
R
2 
R
3 
R
4 
Aromatase 
Estrone 
Sulfatase 
17β-HSD1 
p-Coumaric H H H OH H 80.91 28.81 124.6 
o-Coumaric H OH H H H 78.17 27.27 118.2 
Caffeic H H OH OH H 57.28 19.48 73.97 
Ferulic H H CH3O OH H 26.63 105.5 91.29 
Sinapic CH3O H CH3O OH CH3O 8.260 122.5 27.10 
4-O-caffeoylquinic * H OH OH H 0.315 0.474 0.289 
5-O-caffeoylquinic * H OH OH H 0.760 3.990 0.255 
  
Benzoic acids Cinnamic acids 
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Table 3 
Docking studies with flavonoids found in wild mushrooms. 
O
O
OH
HO
OH
R'1
R'2
R'3
O
O
HO
OH
R'1
R'2
R'3
OHO
OH
R'1
R'2
R'3
OH
O
O
HO
OH
R'1
R'2
R'3
 
O
O
HO
R'1
R'2
R'3  
 Substitution Estimated Ki (µM) 
Flavonols R'1 R'2 R'3 Aromatase Estrone Sulfatase 17β-HSD1 
Quercetin OH OH H 0.316 4.560 0.092 
Rutin* OH OH H 29.80 0.488 0.094 
Kaempferol H OH H 1.090 8.960 0.249 
Myricetin OH OH OH 0.790 5.620 0.091 
Flavones 
Chrysin 
H H H 0.610 15.03 0.467 
Flavan-3-ols 
Catechin 
H OH OH 11.76 11.54 3.210 
Flavanones R'1 R'2 R'3 Aromatase Estrone Sulfatase 17β-HSD1 
Hesperetin OH H H 5.410 7.970 2.310 
Naringenin H OH H 0.342 10.67 0.413 
Naringin * H OH H 0.743 0.206 0.001 
Isoflavones R'1 R'2 R'3 Aromatase Estrone Sulfatase 17β-HSD1 
Formonetim H OCH3 H 590 17.40 0.571 
Biochanin** H OCH3 H 0.710 11.14 0.771 
* OH in position-3 is substituted with the disaccharide rutinose; ** OH in position-5. 
Flavonols Flavones 
 
Flavanones Isoflavones 
Flavan-3-ols 
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Table 4 
Docking studies with vitamins and carotenoids found in wild mushrooms.  
O
HO
R1
R2
       
O
HO
HO
H
OH
CH2OH
O
 
CH3
H3C
H3C CH3
CH3H3C
CH3 CH3
CH3 CH3
 
 Substitution Estimated Ki (µM) 
Tocopherols R1 R2 Aromatase Estrone Sulfatase 17β-HSD1 
α-tocopherol CH3 CH3 41.23 0.672 0.002 
β-tocopherol CH3 H 35.38 1.510 0.009 
γ-tocopherol H CH3 61.36 0.505 0.010 
δ-tocopherol H H 59.68 0.882 0.012 
Ascorbic acid - 277.7 85.87 268.8 
Carotenoids     
β-Carotene - 16.27 > 1 000 0.016 
Lycopene* - > 1 000 5.100 0.0002 
*The rings are opened. 
Carotenoids 
 
Tocopherols Ascorbic acid 
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Table 5 
Docking studies with sugars and fatty acids found in wild mushrooms. 
 Estimated Ki (µM) 
Sugars Aromatase Estrone Sulfatase 17β-HSD1 
Maltose 1.520 3.340 0.605 
Trehalose 9.080 5.650 12.23 
Melezitose > 1 000 > 1 000 > 1 000 
Fatty acids    
Myristic acid (C14:0) 10.59 283.8 56.01 
Palmitic acid (C16:0) 6.940 157.0 12.04 
Stearic acid (C18:0) 2.770 108.6 7.810 
Oleic acid (C18:1n9c) 6.070 84.64 5.070 
Linoleic acid (C18:2n6c) 1.450 28.18 3.730 
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Fig. 1. Superimposition of X-ray (sticks and balls representation) and docked 
conformations (wire representation, black) for: (A) Androstenedione in Aromatase and 
(B) Estrone in 17β-HSD1. The 10 best docked configurations are represented. The 
catalytic residues that form hydrogen bonds (traced lines) with the ligands are shown. 
 
Fig. 2. Color coded representation of the best results obtained by molecular docking of 
the LMW compounds dataset against the 3 protein targets. Colours used are light grey 
for good inhibition activity (< 0.1 μM), white for moderate inhibition activity (0.1 μM > 
Ki > 1 μM) and dark grey for weak or no inhibition activity (Ki > 1 μM). Compounds 
with good or moderate inhibition activity are ordered from best to worst estimated Ki 
value. 
 
Fig. 3. Docking results of the top ranked inhibitor for each of the studied protein targets. 
Figure shows (A) Aromatase, (B) Estrone Sulfatase and (C) 17β-HSD1 docked with 4-
O-caffeoylquinic, naringin and lycopene, respectively. Protein target are represented in 
cartoon format, docked inhibitor in sticks and balls format (red) and natural X-ray 
ligands in wire format (blue). Relevant interactions are shown (traced lines). 
 
 
